Business Context and Reporting Period
This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp as indicated in metadata) on May 23, 2022. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of an interim successor.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: John F. Glenn resigned as Chief Financial Officer, effective June 17, 2022, to join another public company. The resignation is not related to any dispute regarding accounting practices or financial reporting.
- Appointment of Interim CFO: Jerome Wong, the Company's Controller since May 2017, was appointed Interim Chief Financial Officer effective June 17, 2022.
- Compensation Adjustments for Interim CFO:
- Base salary increased from $212,000 to $265,000.
- Target annual discretionary bonus set at 50% of base salary.
- Restricted Stock Units (RSUs) valued at $150,000 (based on June 17, 2022 closing price), vesting in thirds annually.
- Long-Term Incentive Award: Scott Davis, President and COO, received an award of 300,000 RSUs related to his promotion on January 21, 2022, vesting in thirds annually.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies were disclosed other than the standard transition of executive duties.
Investor Verification Checklist
- Verify the effective date of the CFO transition (June 17, 2022) and the interim nature of Jerome Wong's appointment.
- Confirm the valuation of the $150,000 RSU award for Mr. Wong based on the actual stock price on June 17, 2022.
- Review the press release (Exhibit 99.1) for additional context on the leadership transition.
- Note that the filing explicitly states no disagreement exists regarding financial reporting practices.